Moderna CEO Stephane Bancel discusses the development of mRNA vaccines, the technology behind them, and the shift in drug development. He shares the moment he realized a Covid-19 vaccine was possible, explains how mRNA works, and the advantages over traditional vaccines. The episode explores the potential of mRNA technology in treating conditions beyond Covid and the risks involved in biotech.

Stephane Bancel, CEO of Moderna and a key player in the biotech field, shares insights from his experience in navigating the COVID-19 pandemic. He discusses the ethical dilemmas in vaccine development and the importance of diversity in clinical trials. Notably, he reveals innovative hiring practices that emerged during the crisis and the challenges of embracing digital transformation in the pharmaceutical industry. Bancel also reflects on the critical need for public-private partnerships to advance vaccine technology and ensure equitable access.

Modern CEO Stephane Bancel discusses company earnings and cost-cutting benefits in response to Covid business decline. Topics include balancing cost efficiency with innovation, progress on a melanoma vaccine, potential accelerated approval, and the impact of AI on drug production and clinical development.

Citi's economist discusses Fed's interest rate decisions. Bank of America predicts a soft landing post high rates. Moderna CEO talks about better-than-expected earnings and RSV vaccine development.

Moderna CEO discusses market share growth, mRNA vaccines, and plans for new RSV vaccine in 2023. Also explores advancements in RSV, flu, and cancer vaccines, potential of single-shot COVID, flu, and RSV combo vaccine, and competition concerns.